Evidence map›Paper›PMID 29446853›Full record

ArticleCancer science2018

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.

Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 204 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 2 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03589950 phase2unknown statusnot on this map

A Parallel Control, Exploratory Trial to Compare Anlotinib Plus Chemotherapy Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Non-small Cell Lung Cancer

TypeinterventionalSponsorThe First People's Hospital of LianyungangRan2018 to 2021Enrolled60ConditionsLung Neoplasms, Docetaxel, Pemetrexed, S-1Armsanlotinib plus chemotherapy, chemotherapy
NCT06102928 narecruitingnot on this mapstarted 2023, after this paper: background citation

A Prospective, Multicenter, Single-arm Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced Non-small Cell Lung Cancer With EGFR 21L858R Mutation

TypeinterventionalSponsorKunming Medical UniversityRan2023 to 2026Enrolled30ConditionsNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorArmsCombined therapy of anlotinib and aumolertinib
3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 2 syntheses or guidelines pooled it, 365 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  20. Trial

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chengying XieShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xiaozhe WanShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Haitian QuanShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Mingyue ZhengShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Li FuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yun LiShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Liguang LouShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0000-0001-7396-7122
Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abrogating tumor angiogenesis by inhibiting vascular endothelial growth factor receptor-2 (VEGFR2) has been established as a therapeutic strategy for treating cancer. However, because of their low selectivity, most small molecule inhibitors of VEGFR2 tyrosine kinase show unexpected adverse effects and limited anticancer efficacy. In the present study, we detailed the pharmacological properties of anlotinib, a highly potent and selective VEGFR2 inhibitor, in preclinical models. Anlotinib occupied the ATP-binding pocket of VEGFR2 tyrosine kinase and showed high selectivity and inhibitory potency (IC

Indexed as

Angiogenesis InhibitorsAnimalsAntineoplastic AgentsCell LineCell Line, TumorCell ProliferationFemaleHumansHuman Umbilical Vein Endothelial CellsIndolesMaleMiceMice, NudeNeovascularization, PathologicProtein Kinase InhibitorsProtein-Tyrosine KinasesAngiogenesis InhibitorsanlotinibAntineoplastic AgentsIndolesKDR protein, humanProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrrolesQuinolinesSunitinibVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2angiogenesisanlotinibtyrosine kinase inhibitorVEGFVEGFR2

Identifiers

PMID29446853
PMCPMC5891194
OpenAlexW2791667474

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.